Reverse mergers say hey as biotechs trade low, hunt for alternatives and launch few IPOs
The reverse merger announced Wednesday morning between Magenta Therapeutics and privately-held Dianthus Therapeutics, which will take over the Nasdaq spot and push forward its complement pathway drug candidates, highlighted the growing field of such financing moves as dozens of public biotechs search for ways to appease shareholders and as private startups trudge toward Wall Street in an unforgiving IPO environment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.